{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T16:54:44Z","timestamp":1788195284341,"version":"build-2803163510"},"reference-count":83,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T00:00:00Z","timestamp":1568419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>It is well known that hepatitis B virus reactivation (HBVr) can occur among patients undergoing treatment for hematological malignancies (HM). The evaluation of HBVr risk in patients undergoing immunosuppressive treatments is a multidimensional process, which includes conducting an accurate clinical history and physical examination, consideration of the virological categories, of the medication chosen to treat these hematological malignancies and the degree of immunosuppression induced. Once the risk of reactivation has been defined, it is crucial to adopt adequate management strategies (should reactivation occur). The purpose of treatment is to prevent dire clinical consequences of HBVr such as acute\/fulminant hepatitis, and liver failure. Treatment will be instituted according to the indications and evidence provided by current international recommendations and to prevent interruption of lifesaving anti-neoplastic treatments. In this paper, we will present the available data regarding the risk of HBVr in this special population of immunosuppressed patients and explore the relevance of effective prevention and management of this potentially life-threatening event. A computerized literature search was performed using appropriate terms to discover relevant articles. Current evidence supports the policy of universal HBV testing of patients scheduled to undergo treatment for hematological malignancies, and clinicians should be aware of the inherent risk of viral reactivation among the different virological categories and classes of immunosuppressive drugs.<\/jats:p>","DOI":"10.3390\/v11090858","type":"journal-article","created":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T03:17:57Z","timestamp":1568603877000},"page":"858","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Hematological Malignancies and HBV Reactivation Risk: Suggestions for Clinical Management"],"prefix":"10.3390","volume":"11","author":[{"given":"Alessandra","family":"Zannella","sequence":"first","affiliation":[{"name":"Digestive and Liver Diseases Department, Liver Diseases Section, AOU Sant\u2019Andrea Hospital, 00189 Rome, Italy"},{"name":"School of Medicine and Psychology, Sapienza University, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Marignani","sequence":"additional","affiliation":[{"name":"Digestive and Liver Diseases Department, Liver Diseases Section, AOU Sant\u2019Andrea Hospital, 00189 Rome, Italy"},{"name":"School of Medicine and Psychology, Sapienza University, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Begini","sequence":"additional","affiliation":[{"name":"Digestive and Liver Diseases Department, Liver Diseases Section, AOU Sant\u2019Andrea Hospital, 00189 Rome, Italy"},{"name":"School of Medicine and Psychology, Sapienza University, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,9,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0016-5085(75)80054-0","article-title":"Serial Studies of Hepatitis-Associated Antigen and Antibody in Patients Receiving Antitumor Chemotherapy for Myeloproliferative and Lymphoproliferative Disorders","volume":"68","author":"Wands","year":"1975","journal-title":"Gastroenterology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0140-6736(75)90897-1","article-title":"Fulminant Hepatic Failure in Leukaemia and Choriocarcinoma Related To Withdrawal of Cytotoxic Drug Therapy","volume":"306","author":"Galbraith","year":"1975","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S0140-6736(77)91995-X","article-title":"Reactivation of Hepatitis B After Transplantation Operations","volume":"309","author":"Nagington","year":"1977","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/0016-5085(81)90080-9","article-title":"Reactivation of Hepatitis B Virus Infection in Two Patients: Immunofluorescence Studies of Liver Tissue","volume":"80","author":"Villa","year":"1981","journal-title":"Gastroenterology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"447","DOI":"10.7326\/0003-4819-96-4-447","article-title":"Reactivation of Chronic Hepatitis B Virus Infection by Cancer Chemotherapy","volume":"96","author":"Hoofnagle","year":"1982","journal-title":"Ann. Intern. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/jmv.1890150105","article-title":"Hepatitis B Virus Markers in Children with Acute Leukemia: The Effect of Chemotherapy","volume":"15","author":"Locasciulli","year":"1985","journal-title":"J. Med. Virol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1001\/archinte.1985.00360070195034","article-title":"Massive Hepatic Necrosis after Chemotherapy Withdrawal in a Hepatitis B Virus Carrier","volume":"145","author":"Thung","year":"1985","journal-title":"Arch. Intern. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/pgmj.64.750.325","article-title":"Fulminant Hepatic Failure in Nephrotic Syndrome Related to Withdrawal of Immunosuppressive Therapy","volume":"64","author":"Onwubalili","year":"1988","journal-title":"Postgrad. Med. J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/BF01535798","article-title":"Fulminant Hepatitis Due to Reactivation of Chronic Hepatitis B Virus Infection after Allogeneic Bone Marrow Transplantation","volume":"33","author":"Pariente","year":"1988","journal-title":"Dig. Dis. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00007890-198503000-00021","article-title":"Fulminant Hepatic Failure in an HBsAg Carrier Renal Transplant Patient Following Cessation of Immunosuppressive Therapy","volume":"39","author":"Hanson","year":"1985","journal-title":"Transplantation"},{"key":"ref_11","first-page":"207","article-title":"Fatal Hepatitis B Reactivation after Autologous Bone Marrow Transplantation","volume":"4","author":"Webster","year":"1989","journal-title":"Bone Marrow Transpl."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/0168-8278(89)90012-3","article-title":"Recurrence of Hepatitis B in Children with Serologic Evidence of Past Hepatitis B Virus Infection Undergoing Antileukemic Chemotherapy","volume":"8","author":"Panzer","year":"1989","journal-title":"J. Hepatol."},{"key":"ref_13","first-page":"911","article-title":"Fatal Reactivation of Chronic Hepatitis B Virus Infection Following Withdrawal of Chemotherapy in Lymphoma Patients","volume":"73","author":"Lau","year":"1989","journal-title":"Q. J. Med."},{"key":"ref_14","first-page":"895","article-title":"Acute Liver Decompensation on Withdrawal of Cytotoxic Chemotherapy and Immunosuppressive Therapy in Hepatitis B Carriers","volume":"73","author":"Bird","year":"1989","journal-title":"Q. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"381","DOI":"10.7326\/0003-4819-112-5-381","article-title":"Fulminant Hepatitis as a Consequence of Reactivation of Hepatitis B Virus Infection after Discontinuation of Low-Dose Methotrexate Therapy","volume":"112","author":"Flowers","year":"1990","journal-title":"Ann. Intern. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hon.2900080504","article-title":"Hepatitis B Infection in Patients with Lymphomas","volume":"8","author":"Liang","year":"1990","journal-title":"Hematol. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/0016-5085(91)90599-G","article-title":"Reactivation of Hepatitis B Virus Replication in Patients Receiving Cytotoxic Therapy Report of a Prospective Study","volume":"100","author":"Lok","year":"1991","journal-title":"Gastroenterology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"A112","DOI":"10.1016\/0270-9139(93)91978-2","article-title":"Phase II Trial of Lamivudine for Chronic Hepatitis B","volume":"18","author":"Tyrrell","year":"1993","journal-title":"Hepatology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJM199512213332501","article-title":"A Preliminary Trial of Lamivudine for Chronic Hepatitis B Infection","volume":"333","author":"Dienstag","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1572-0241.1999.00808.x","article-title":"Lamivudine Therapy for Chemotherapy-Induced Reactivation of Hepatitis B Virus Infection","volume":"94","author":"Ahmed","year":"1999","journal-title":"Am. J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1053\/j.gastro.2003.09.026","article-title":"Early Is Superior to Deferred Preemptive Lamivudine Therapy for Hepatitis B Patients Undergoing Chemotherapy","volume":"125","author":"Lau","year":"2003","journal-title":"Gastroenterology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1200\/JCO.2004.05.161","article-title":"Lamivudine for the Prevention of Hepatitis B Virus Reactivation in Hepatitis B S-Antigen Seropositive Cancer Patients Undergoing Cytotoxic Chemotherapy","volume":"22","author":"Yeo","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/hep.22106","article-title":"A Revisit of Prophylactic Lamivudine for Chemotherapy-Associated Hepatitis B Reactivation in Non-Hodgkin\u2019s Lymphoma: A Randomized Trial","volume":"47","author":"Hsu","year":"2008","journal-title":"Hepatology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1200\/JCO.2012.48.5938","article-title":"Randomized Controlled Trial of Entecavir Prophylaxis for Rituximab-Associated Hepatitis B Virus Reactivation in Patients With Lymphoma and Resolved Hepatitis B","volume":"31","author":"Huang","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2008.18.0182","article-title":"Hepatitis B Virus Reactivation in Lymphoma Patients with Prior Resolved Hepatitis B Undergoing Anticancer Therapy with or without Rituximab","volume":"27","author":"Yeo","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1200\/JCO.2010.29.7531","article-title":"Prospective Analysis of Hepatitis B Virus Reactivation in Patients with Diffuse Large B-Cell Lymphoma after Rituximab Combination Chemotherapy","volume":"28","author":"Niitsu","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1001\/jama.2014.15704","article-title":"Entecavir vs Lamivudine for Prevention of Hepatitis B Virus Reactivation Among Patients With Untreated Diffuse Large B-Cell Lymphoma Receiving R-CHOP Chemotherapy","volume":"312","author":"Huang","year":"2014","journal-title":"JAMA"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Evens, A.M., Jovanovic, B.D., Su, Y.C., Raisch, D.W., Ganger, D., Belknap, S.M., Dai, M.S., Chiu, B.C.C., Finte, B., and Cheng, Y. (2011). Rituximab-Associated Hepatitis B Virus (HBV) Reactivation in Lymphoproliferative Diseases: Metaanalysis and Examination of FDA Safety Reports. Ann. Oncol.","DOI":"10.1093\/annonc\/mdq583"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1365-2893.2007.00902.x","article-title":"Lamivudine Prevents Reactivation of Hepatitis B and Reduces Mortality in Immunosuppressed Patients: Systematic Review and Meta-Analysis","volume":"15","author":"Katz","year":"2008","journal-title":"J. Viral Hepat."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3324\/haematol.2018.210252","article-title":"Reactivation of Hepatitis B Virus Infection in Patients with Hematologic Disorders","volume":"104","author":"Wang","year":"2019","journal-title":"Haematologica"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13027-018-0190-9","article-title":"Negative Effect of Hepatitis in Overall and Progression-Free Survival among Patients with Diffuse Large B-Cell Lymphoma","volume":"13","author":"Alghamdi","year":"2018","journal-title":"Infect. Agent. Cancer"},{"key":"ref_32","first-page":"1","article-title":"Recommendations for Identification and Public Health Management of Persons with Chronic Hepatitis B Virus Infection","volume":"57","author":"Weinbaum","year":"2008","journal-title":"MMWR. Recomm. reports Morb. Mortal. Wkly. report. Recomm. reports"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection","volume":"67","author":"Lampertico","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.dld.2006.12.017","article-title":"Prophylaxis and Treatment of Hepatitis B in Immunocompromised Patients","volume":"39","author":"Marzano","year":"2007","journal-title":"Dig. Liver Dis."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Perrillo, R.P., Gish, R., Ytter, Y.T.F., and Agaf, M.D. (2015). American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Reactivation During Immunosuppressive Drug Therapy Palo Alto, California Hepatitis B Foundation, PA Division of Gastroenterology and Hepatolog. Gastroenterology.","DOI":"10.1053\/j.gastro.2014.10.038"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Sarin, S.K., Kumar, M., Lau, G.K., Abbas, Z., Chan, H.L.Y., Chen, C.J., Chen, D.S., Chen, H.L., Chen, P.J., and Chien, R.N. (2016). Asian-Pacific Clinical Practice Guidelines on the Management of Hepatitis B: A 2015 Update. Hepatol. Int.","DOI":"10.1007\/s12072-015-9675-4"},{"key":"ref_37","unstructured":"(2019, September 09). Associazione Italiana per lo Studio del Fegato Gestione Clinica della Epatite B negli Immunocompromessi: Aggiornamento Italiano 2017. Available online: https:\/\/www.webaisf.org\/media\/37755\/gestione_clinica_della_epatite_b_negli_immunocompromessi.2017.pdf."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2010.30.0673","article-title":"American Society of Clinical Oncology Provisional Clinical Opinion: Chronic Hepatitis B Virus Infection Screening in Patients Receiving Cytotoxic Chemotherapy for Treatment of Malignant Diseases","volume":"28","author":"Artz","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jhep.2008.07.014","article-title":"Statements from the Taormina Expert Meeting on Occult Hepatitis B Virus Infection","volume":"49","author":"Raimondo","year":"2008","journal-title":"J. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Salpini, R., Colagrossi, L., Bellocchi, M.C., Surdo, M., Becker, C., Alteri, C., Aragri, M., Ricciardi, A., Armenia, D., and Pollicita, M. (2015). Hepatitis B Surface Antigen Genetic Elements Critical for Immune Escape Correlate with Hepatitis B Virus Reactivation upon Immunosuppression. Hepatology.","DOI":"10.1002\/hep.27604"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Brunetto, M.R., Oliveri, F., Colombatto, P., Moriconi, F., Ciccorossi, P., Coco, B., Romagnoli, V., Cherubini, B., Moscato, G., and Maina, A.M. (2010). Hepatitis B Surface Antigen Serum Levels Help to Distinguish Active from Inactive Hepatitis B Virus Genotype D Carriers. Gastroenterology.","DOI":"10.1053\/j.gastro.2010.04.052"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Brouwer, W.P., Chan, H.L.Y., Brunetto, M.R., Martinot-Peignoux, M., Arends, P., Cornberg, M., Cherubini, B., Thompson, A.J.V., Liaw, Y.F., and Marcellin, P. (2016). Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-Term Follow-Up. Clin. Gastroenterol. Hepatol.","DOI":"10.1016\/j.cgh.2016.01.019"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/hep.22518","article-title":"Is There a Meaningful Serum Hepatitis B Virus DNA Cutoff Level for Therapeutic Decisions in Hepatitis B e Antigen-Negative Chronic Hepatitis B Virus Infection?","volume":"48","author":"Papatheodoridis","year":"2008","journal-title":"Hepatology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/gutjnl-2011-301096","article-title":"Quantification of Serum Hepatitis B Surface Antigen: Is It Useful for the Management of Chronic Hepatitis B?","volume":"61","author":"Janssen","year":"2012","journal-title":"Gut"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.4254\/wjh.v9.i25.1043","article-title":"Hepatitis B in Patients with Hematological Diseases: An Update","volume":"9","author":"Coluccio","year":"2017","journal-title":"World J. Hepatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1001\/jamaoncol.2018.6437","article-title":"Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection among Patients with Newly Diagnosed Cancer from Academic and Community Oncology Practices","volume":"5","author":"Ramsey","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Lee, R.S.M., Bell, C.M., Singh, J.M., and Hicks, L.K. (2012). Hepatitis B Screening Before Chemotherapy: A Survey of Practitioners\u2019 Knowledge, Beliefs, and Screening Practices. J. Oncol. Pract.","DOI":"10.1200\/JOP.2012.000597"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.3109\/10428194.2013.879712","article-title":"Perception of Hepatitis B Virus Infection Reactivation-Related Issues among Specialists Managing Hematologic Malignancies: Result of an Italian Survey","volume":"55","author":"Marignani","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4251\/wjgo.v4.i3.37","article-title":"Patients with Hematological Malignancies and Serological Signs of Prior Resolved Hepatitis B","volume":"4","author":"Marignani","year":"2012","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Gentile, G., Andreoni, M., Antonelli, G., and Sarmati, L. (2017). Screening, Monitoring, Prevention, Prophylaxis and Therapy for Hepatitis B Virus Reactivation in Patients with Haematologic Malignancies and Patients Who Underwent Haematologic Stem Cell Transplantation: A Systematic Review. Clin. Microbiol. Infect. Dis., 23.","DOI":"10.1016\/j.cmi.2017.06.024"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/jvh.12402","article-title":"Hepatitis B Reactivation in HBsAg-Negative\/HBcAb-Positive Patients Receiving Rituximab for Lymphoma: A Meta-Analysis","volume":"22","author":"Mozessohn","year":"2015","journal-title":"J. Viral Hepat."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jcv.2013.03.010","article-title":"Risk of Hepatitis B Virus (HBV) Reactivation in Non-Hodgkin Lymphoma Patients Receiving Rituximab-Chemotherapy: A Meta-Analysis","volume":"57","author":"Dong","year":"2013","journal-title":"J. Clin. Virol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Wu, C.Y., Hsiao, L.T., Chiou, T.J., Gau, J.P., Liu, J.H., Yu, Y.B., Wu, Y.T., Liu, C.J., Huang, Y.C., and Hung, M.H. (2015). Lymphocyte\/Monocyte Ratio and Cycles of Rituximab-Containing Therapy Are Risk Factors for Hepatitis B Virus Reactivation in Patients with Diffuse Large B-Cell Lymphoma and Resolved Hepatitis B. Leuk. Lymphoma.","DOI":"10.3109\/10428194.2014.991922"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Giaccone, L., Festuccia, M., Marengo, A., Resta, I., Sorasio, R., Pittaluga, F., Fiore, F., Boccadoro, M., Rizzetto, M., and Bruno, B. (2010). Hepatitis B Virus Reactivation and Efficacy of Prophylaxis with Lamivudine in Patients Undergoing Allogeneic Stem Cell Transplantation. Biol. Blood Marrow Transplant.","DOI":"10.1016\/j.bbmt.2009.12.533"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Seto, W.K., Chan, T.S.Y., Hwang, Y.Y., Wong, D.K.H., Fung, J., Liu, K.S.H., Gill, H., Lam, Y.F., Lie, A.K.W., and Lai, C.L. (2014). Hepatitis B Reactivation in Patients with Previous Hepatitis B Virus Exposure Undergoing Rituximab-Containing Chemotherapy for Lymphoma: A Prospective Study. J. Clin. Oncol.","DOI":"10.1200\/JCO.2014.56.7081"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Yu, S., Luo, H., Pan, M., Luis, A.P., Xiong, Z., Shuai, P., and Zhang, Z. (2016). Comparison of Entecavir and Lamivudine in Preventing HBV Reactivation in Lymphoma Patients Undergoing Chemotherapy: A Meta-Analysis. Int. J. Clin. Pharm.","DOI":"10.1007\/s11096-016-0358-6"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/sj.bjc.6601699","article-title":"Comprehensive Analysis of Risk Factors Associating with Hepatitis B Virus (HBV) Reactivation in Cancer Patients Undergoing Cytotoxic Chemotherapy","volume":"90","author":"Yeo","year":"2004","journal-title":"Br. J. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1182\/blood.V99.7.2324","article-title":"High Hepatitis B Virus (HBV) DNA Viral Load as the Most Important Risk Factor for HBV Reactivation in Patients Positive for HBV Surface Antigen Undergoing Autologous Hematopoietic Cell Transplantation","volume":"99","author":"Lau","year":"2002","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Chen, W.-C., Cheng, J.-S., Chiang, P.-H., Tsay, F.-W., Chan, H.-H., Chang, H.-W., Yu, H.-C., Tsai, W.-L., Lai, K.-H., and Hsu, P.-I. (2015). A Comparison of Entecavir and Lamivudine for the Prophylaxis of Hepatitis B Virus Reactivation in Solid Tumor Patients Undergoing Systemic Cytotoxic Chemotherapy. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0131545"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1055\/s-0033-1345722","article-title":"Immunosuppression and HBV Reactivation","volume":"33","author":"Shouval","year":"2013","journal-title":"Semin. Liver Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3350\/cmh.2016.0024","article-title":"Prevention of Hepatitis B Reactivation in the Setting of Immunosuppression","volume":"2","author":"Pattullo","year":"2016","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood-2018-04-848044","article-title":"Risk of HBV Reactivation in Patients with B-Cell Lymphomas Receiving Obinutuzumab or Rituximab Immunochemotherapy","volume":"133","author":"Kusumoto","year":"2019","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1445-5994.2009.02060.x","article-title":"Prevalence of Hepatitis B Virus Infection in Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis","volume":"40","author":"Nath","year":"2010","journal-title":"Intern. Med. J."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Feyler, S., Selby, P.J., and Cook, G. (2013). Regulating the Regulators in Cancer-Immunosuppression in Multiple Myeloma (MM). Blood Rev.","DOI":"10.1016\/j.blre.2013.04.004"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Mya, D.H.T., Han, S.T., Linn, Y.C., Hwang, W.Y.K., Goh, Y.T., and Tan, D.C.L. (2012). Risk of Hepatitis B Reactivation and the Role of Novel Agents and Stem-Cell Transplantation in Multiple Myeloma Patients with Hepatitis B Virus (HBV) Infection. Ann. Oncol.","DOI":"10.1093\/annonc\/mdr142"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Chen, C.Y., Huang, S.Y., Cheng, A., Chou, W.C., Yao, M., Tang, J.L., Tsay, W., Sheng, W.H., and Tien, H.F. (2015). High Risk of Hepatitis B Reactivation among Patients with Acute Myeloid Leukemia. PLoS ONE.","DOI":"10.1371\/journal.pone.0126037"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1002\/hep.26718","article-title":"Chemotherapy-Induced Hepatitis B Reactivation in Lymphoma Patients with Resolved HBV Infection: A Prospective Study","volume":"59","author":"Hsu","year":"2014","journal-title":"Hepatology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/hep.29082","article-title":"Role of Surface Antibody in Hepatitis B Reactivation in Patients with Resolved Infection and Hematologic Malignancy: A Meta-Analysis","volume":"66","author":"Paul","year":"2017","journal-title":"Hepatology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jhep.2018.02.033","article-title":"Quantification of HBV Core Antibodies May Help Predict HBV Reactivation in Patients with Lymphoma and Resolved HBV Infection","volume":"69","author":"Yang","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1073\/pnas.83.6.1627","article-title":"Hepatitis B Virus DNA Contains a Glucocorticoid-Responsive Element","volume":"83","author":"Burk","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Wang, J., Jia, J., Chen, R., Ding, S., Xu, Q., Zhang, T., Chen, X., Liu, S., and Lu, F. (2018). RFX1 Participates in Doxorubicin-Induced Hepatitis B Virus Reactivation. Cancer Med.","DOI":"10.1002\/cam4.1468"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Law, M.F., Ho, R., Cheung, C.K.M., Tam, L.H.P., Ma, K., So, K.C.Y., Ip, B., So, J., Lai, J., and Ng, J. (2016). Prevention and Management of Hepatitis B Virus Reactivation in Patients with Hematological Malignancies Treated with Anticancer Therapy. World J. Gastroenterol.","DOI":"10.3748\/wjg.v22.i28.6484"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Di Bisceglie, A.M., Lok, A.S., Martin, P., Terrault, N., Perrillo, R.P., and Hoofnagle, J.H. (2015). Recent US Food and Drug Administration Warnings on Hepatitis B Reactivation with Immune-Suppressing and Anticancer Drugs: Just the Tip of the Iceberg?. Hepatology.","DOI":"10.1002\/hep.27609"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Mikulska, M., Lanini, S., Gudiol, C., Drgona, L., Ippolito, G., Fern\u00e1ndez-Ruiz, M., and Salzberger, B. (2018). ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the Safety of Targeted and Biological Therapies: An Infectious Diseases Perspective (Agents Targeting Lymphoid Cells Surface Antigens [I]: CD19, CD20 and CD52). Clin. Microbiol. Infect.","DOI":"10.1016\/j.cmi.2018.02.003"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Reinwald, M., Silva, J.T., Mueller, N.J., Fort\u00fan, J., Garzoni, C., de Fijter, J.W., Fern\u00e1ndez-Ruiz, M., Grossi, P., and Aguado, J.M. (2018). ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the Safety of Targeted and Biological Therapies: An Infectious Diseases Perspective (Intracellular Signaling Pathways: Tyrosine Kinase and MTOR Inhibitors). Clin. Microbiol. Infect.","DOI":"10.1016\/j.cmi.2018.02.009"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/j.cmi.2018.03.022","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the Safety of Targeted and Biological Therapies: An Infectious Diseases Perspective (Agents Targeting Lymphoid or Myeloid Cells Surface Antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4)","volume":"24","author":"Drgona","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Vigan\u00f2, M., Serra, G., Casella, G., Grossi, G., and Lampertico, P. (2016). Reactivation of Hepatitis B Virus during Targeted Therapies for Cancer and Immune-Mediated Disorders. Expert Opin. Biol. Ther.","DOI":"10.1080\/14712598.2016.1177017"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Loomba, R., and Liang, T.J. (2017). Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions. Gastroenterology.","DOI":"10.1053\/j.gastro.2017.02.009"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Salpini, R., Battisti, A., Colagrossi, L., di Carlo, D., Fabeni, L., Piermatteo, L., Cerva, C., Lichtner, M., Mastroianni, C., and Marignani, M. (2019). A Snapshot of Virological Presentation and Outcome of Immunosuppression-Driven HBV Reactivation from Real Clinical Practice: Evidence of a Relevant Risk of Death and Evolution from Silent to Chronic Infection. J. Viral Hepat.","DOI":"10.1111\/jvh.13101"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"946.e1","DOI":"10.1016\/j.cmi.2016.07.021","article-title":"Persistent Risk of HBV Reactivation despite Extensive Lamivudine Prophylaxis in Haematopoietic Stem Cell Transplant Recipients Who Are Anti-HBc-Positive or HBV-Negative Recipients with an Anti-HBc-Positive Donor","volume":"22","author":"Cerva","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/jvh.12802","article-title":"Eighteen-Month Lamivudine Prophylaxis on Preventing Occult Hepatitis B Virus Infection Reactivation in Patients with Haematological Malignancies Receiving Immunosuppression Therapy","volume":"25","author":"Marrone","year":"2018","journal-title":"J. Viral Hepat."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.dld.2018.08.024","article-title":"Lamivudine Prophylaxis Prevents Hepatitis B Virus Reactivation in Anti-HBc Positive Patients under Rituximab for Non-Hodgkin Lymphoma","volume":"51","author":"Loglio","year":"2019","journal-title":"Dig. Liver Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.clml.2018.11.008","article-title":"Prophylactic Use of Entecavir for Lymphoma Patients With Past Hepatitis B Virus Infection: A Randomized Controlled Trial","volume":"19","author":"Liu","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/11\/9\/858\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:20:16Z","timestamp":1760188816000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/11\/9\/858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,14]]},"references-count":83,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,9]]}},"alternative-id":["v11090858"],"URL":"https:\/\/doi.org\/10.3390\/v11090858","relation":{"has-preprint":[{"id-type":"doi","id":"10.20944\/preprints201907.0282.v1","asserted-by":"object"}]},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,14]]}}}